-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Author: Wu Yue
On September 29, Shanghai Hengrui Medicine submitted an application for the listing of a new drug class 2.
Picture 1: Hengrui's latest product declaration
Source: CDE official website
Figure 2: Changes in the share of dexmedetomidine hydrochloride injection TOP3 companies
Source: Mi Nei.
Dexmedetomidine is an α2 adrenergic receptor agonist, mainly used for tracheal intubation and sedation during mechanical ventilation in patients undergoing general anesthesia
Before 2018, Hengrui was the leading company in dexmedetomidine hydrochloride injection, with a market share of more than 80%.
In the wave of centralized procurement and price reduction, dexmedetomidine hydrochloride injection still maintains a rapid growth trend.
Table 1: Application status of new formulations related to dexmedetomidine
Source: Meinenet MED2.
Including Hengrui, there are Wuxi Jiyushanhe Pharmaceuticals and Sichuan Prime Medical Technology to deploy dexmedetomidine nasal spray (nasal spray) products.
Source: CDE official website, Minet database
The review data statistics are as of September 30, if there are any errors or omissions, please correct me